Regulation of myosin light chain kinase expression by angiotensin II in hypertension

American Journal of Hypertension

Volumn 21, Issue 8, 2008, Pages 860-865

  Han, Yoo Jeong ^a   Hu, Wen Yang ^a   Piano, Mariann ^b   De Lanerolle, Primal ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYOSIN LIGHT CHAIN KINASE; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; HYPERTENSION; MALE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER; SPHYGMOMANOMETRY; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; WESTERN BLOTTING; WISTAR KYOTO RAT;

ANGIOTENSIN II; ANIMALS; AORTA; AZEPINES; BLOOD PRESSURE; CELLS, CULTURED; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HYPERTENSION; MUSCLE, SMOOTH, VASCULAR; MYOSIN-LIGHT-CHAIN KINASE; NAPHTHALENES; RAS PROTEINS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; VASOCONSTRICTOR AGENTS;

EID: 47749106786     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.199     Document Type: Article

References (33)

1. Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005; 18:720-730.
2. Touyz RM. The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 2003; 5:155-164.
3. Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 1987; 9:178-187.
4. Azuma H, Niimi Y, Hamasaki H. Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan. Br J Pharmacol 1992; 106:665-671.
5. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3:459-465.
6. Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, DeCaprio JA, Ewen ME. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 1997; 386:177-181.
7. Chien KR, Hoshijima M. Unravelling Ras signals in cardiovascular disease. Nat Cell Biol 2004; 6:807-808.
8. Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D, Li P, Qiu X, Wen S, Xiao RP, Tang J. Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol 2004; 6:872-883.
9. de Lanerolle P, Paul RJ. Myosin phosphorylation/dephosphorylation and regulation of airway smooth muscle contractility. Am J Physiol 1991; 261:L1-L14.
10. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature 1994; 372:231-236.
11. Feng J, Ito M, Ichikawa K, Isaka N, Nishikawa M, Hartshorne DJ, Nakano T. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem 1999; 274:37385-37390.
12. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996; 273:245-248.
13. Seasholtz TM, Zhang T, Morissette MR, Howes AL, Yang AH, Brown JH. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats. Circ Res 2001; 89:488-495.
14. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389:990-994.
15. Dostal DE, Murahashi T, Peach MJ. Regulation of cytosolic calcium by angiotensins in vascular smooth muscle. Hypertension 1990; 15:815-822.
16. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963; 27:282-293.
17. Owens GK, Schwartz SM. Alterations in vascular smooth muscle mass in the spontaneously hypertensive rat. Role of cellular hypertrophy, hyperploidy, and hyperplasia. Circ Res 1982; 51:280-289.
18. Stephens NL. Mechanical properties of vascular smooth muscle in hypertension. Clin Invest Med 1987; 10:536-542.
19. Ross R. The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 1971; 50:172-186.
20. Chew TL, Wolf WA, Gallagher PJ, Matsumura F, Chisholm RL. A fluorescent resonant energy transfer-based biosensor reveals transient and regional myosin light chain kinase activation in lamella and cleavage furrows. J Cell Biol 2002; 156:543-553.
21. de Lanerolle P, Adelstein RS, Feramisco JR, Burridge K. Characterization of antibodies to smooth muscle myosin kinase and their use in localizing myosin kinase in nonmuscle cells. Proc Natl Acad Sci USA 1981; 78:4738-4742.
22. Lessard JL. Two monoclonal antibodies to actin: one muscle selective and one generally reactive. Cell Motil Cytoskeleton 1988; 10:349-362.
23. 2+ and calmodulin-independent contraction of smooth muscle. Pflugers Arch 1989; 414:134-138.
24. Han YJ, Hu WY, Chernaya O, Antic N, Gu L, Gupta M, Piano M, de Lanerolle P. Increased myosin light chain kinase expression in hypertension: regulation by serum response factor via an insertion mutation in the promoter. mol Biol Cell 2006; 17:4039-4050.
25. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273:18623-18632.
26. Saleh FH, Jurjus AR. A comparative study of morphological changes in spontaneously hypertensive rats and normotensive Wistar Kyoto rats treated with an angiotensin-converting enzyme inhibitor or a calcium-channel blocker. J Pathol 2001; 193:415-420.
27. Jordan P, Karess R. Myosin light chain-activating phosphorylation sites are required for oogenesis in Drosophila. J Cell Biol 1997; 139:1805-1819.
28. Simerly C, Nowak G, de Lanerolle P, Schatten G. Differential expression and functions of cortical myosin IIA and IIB isotypes during meiotic maturation, fertilization, and mitosis in mouse oocytes and embryos. mol Biol Cell 1998; 9:2509-2525.
29. Komatsu S, Yano T, Shibata M, Tuft RA, Ikebe M. Effects of the regulatory light chain phosphorylation of myosin II on mitosis and cytokinesis of mammalian cells. J Biol Chem 2000; 275:34512-34520.
30. Fazal F, Gu L, Ihnatovych I, Han Y, Hu W, Antic N, Carreira F, Blomquist JF, Hope TJ, Ucker DS, de Lanerolle P. Inhibiting myosin light chain kinase induces apoptosis in vitro and in vivo. mol Cell Biol 2005; 25:6259-6266.
31. Gu LZ, Hu WY, Antic N, Mehta R, Turner JR, de Lanerolle P. Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells. Eur J Cancer 2006; 42:948-957.
32. Hu WY, Han YJ, Gu LZ, Piano M, de Lanerolle P. Involvement of Ras-regulated myosin light chain phosphorylation in the captopril effects in spontaneously hypertensive rats. Am J Hypertens 2007; 20:53-61.
33. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997; 137:481-492.